Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2014 Earnings Presentation
11 slides from Anika Therapeutics's earnings presentation, Jul 31, 2014
Slide 1: Anika Therapeutics, Inc. Second Quarter 2014 Investor Conference Call
Anika Therapeutics, Inc. Second Quarter 2014 Investor Conference Call July 31, 2014 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known a
Slide 3: Overview
Overview Solid second quarter results • Total revenue up 26% to $26.3M Includes $5M in milestone revenue associated with U.S. license agreement for Monovisc® • Orthobiologics product revenue up 11% year over year Driven by product sales and royalty revenue associated with Monovisc® US launch • Chang
Slide 4: Income Statement Highlights
Income Statement Highlights Solid bottom-line performance in Q2 2014 Dollars in millions, Q2 2013 Q2 2014 %Δ except per- share amounts Total Revenue $20.8 $26.3 26% Product Gross Margin 69% 75% Operating Expenses $11.4 $11.1 (3)% Operating Income $9.4 $15.2 62% Net Income $5.9 $9.3 58% Diluted EPS $
Slide 5: Balance Sheet Highlights
Balance Sheet Highlights Increased cash and strong working capital position (In millions) 12/31/13 6/30/14 $22M cash increase • U.S. Monovisc® milestone Cash & Cash Equivalents $63.3 $84.9 payments Working Capital $85.3 $112.2 • Strong cash from operations Stockholders’ Equity $135.6 $162.4 • Exerci
Slide 6: Orthobiologics Highlights
Orthobiologics Highlights U.S. Monovisc® commercial launch and first domestic sales • Sales in line with expectations • Successful CMS meeting in May, and made progress toward achieving a unique reimbursement J-Code • Marketing strategy maintains brand recognition for Orthovisc® in multiple-injectio
Slide 7: Viscosupplementation Overview
Viscosupplementation Overview Progress on global viscosupplementation market share strategy • Strategic goal: achieve 15% global viscosupplementation market share by the end of 2018 1. Leverage U.S. brand leadership to drive global Monovisc® and Orthovisc® growth 2. Expand international distribution
Slide 8: Advanced Wound Care Franchise Update
Advanced Wound Care Franchise Update Progress on global advanced wound care franchise expansion • Making good progress in strengthening our established international distribution networks • Expanding into new geographic markets, primarily in the U.S. and South America • Entered into an exclusive com
Slide 9: Product Pipeline
Product Pipeline Focused on Cingal™ and Hyalofast™ • Cingal o Complete clinical trial and submit CE Mark application by year-end 2014 or shortly thereafter o Preliminary discussions with FDA followed by formal meeting in 2H 2014 • Hyalofast o Continued progress to make available as one-step cartilag
Slide 10: 2014 Business Outlook
2014 Business Outlook Well-positioned for second half 2014 • Executing on strategy to capture share in global viscosupplementation market • Increased demand for Orthovisc® and Monovisc® • CingalTM and HyalofastTM advancing toward commercialization • Adding organizational and operational capabilities
Slide 11: Anika Therapeutics, Inc. Second Quarter 2014 Investor Conference Call
Anika Therapeutics, Inc. Second Quarter 2014 Investor Conference Call July 31, 2014 11